Thursday, 10 October 2019
Bluefish Pharmaceuticals wins important Tender in Germany
Once again Bluefish Pharma has proven to be one of the world’s most progressive generic pharmaceuticals companies: In the latest Tender (XXII) of the German health insurance AOK, Bluefish has been awarded exclusivity for 4 products.
AOK is Germany’s largest health insurance company with approximately 26 Mio members and is Germanys most important health insurance that covers about 36% of the German population. Bluefish was exclusively chosen for four products in this contract, that will start in April 2020 for a 22 months contract period including about 350.000 packs.
The sales value based on ex-factory-price (i.e. list prices before discounts) of these four tender products to the AOK patients is about 22 Mio. EUR. Tender prices are in general considerably lower than ex-factory prices.
"We are very pleased with the results of the tender, which is an important milestone in terms of increasing our market share in German generics market," said Berit Lindholm CEO of Bluefish Pharmaceuticals.
Germany’s Country Manger Daniela Stoppel comments the tender award: “This is an important step and a clear signal that Bluefish is perfectly suited to meet the needs of the German generic market. We are regarded as stable partner able to reliable deliver high quality products at competitive prices.”
For more information, contact
Berit Lindholm, CEO Bluefish Pharmaceuticals
Tel. 46 8 519 116 00
About Bluefish Pharmaceuticals
Bluefish has undergone significant international expansion since the company was founded in 2005. Bluefish focuses on the development, manufacture and sale of generic pharmaceuticals. The company conducts marketing operations in a large number of European markets and is expanding into territories outside Europe. The product portfolio consists of a total of approximately 80 products and is growing.